Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target.

Jawaria, Yusra Zarlashat, Márton Philippovich, Edit Dósa

Abstract readReview

In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

The Sirtuin Network: Linking NADDiabetes/metabolism research and reviews · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

JawariaHealth Biotechnology Division, National Institute for Biotechnology and Genetic Engineering-C (NIBGE), Faisalabad 38000, Pakistan.

Yusra ZarlashatDepartment of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan.ORCID 0009-0000-8744-2255

Márton PhilippovichHeart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.

Edit DósaHeart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.ORCID 0000-0003-2984-2642

Funding

National Research, Development, and Innovation Fund of Hungary NKFI-K-146929

6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, arising from complex interactions among metabolic, genetic, and environmental factors. Nicotinamide N-methyltransferase (NNMT) has recently emerged as a key metabolic regulator in CVD pathogenesis. By consuming nicotinamide and methyl groups, NNMT perturbs epigenetic, metabolic, and redox pathways that are critical for cardiovascular health. NNMT-mediated NAD

Indexed as

Cardiovascular DiseasesNicotinamide N-MethyltransferaseAnimalsHumansNiacinamideNiacinamideNicotinamide N-Methyltransferaseatherosclerosiscardiovascular diseaseNAD+ metabolismnicotinamide N-methyltransferaseNNMT inhibitorsoxidative stresssirtuins

Identifiers

PMID41008588

DOI10.3390/biom15091281

PMCPMC12467181

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.